CLOs on the Move

KV Pharmaceutical Company

www.kvpharmaceutical.com

 
KV Pharmaceutical Company is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

Medicure

Medicure, Inc. is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Akari Therapeutics

Akari Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5). Its lead drug, Covers...

DK Sinopharma

DK Sinopharma is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Santen

At Santen, we`re innovating therapies to improve the quality of life for patients worldwide. Our single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a global company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Our clinical development network now spans three continents, with centers in EMEA (Europe, the Middle East and Africa), Japan, and the United States.

Clinical ink

Clinical ink is the global life science company that brings data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.